Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43307
UPID:
ARHG9_HUMAN
Alternative names:
Collybistin; PEM-2 homolog; Rac/Cdc42 guanine nucleotide exchange factor 9
Alternative UPACC:
O43307; A8K1S8; B4DHC7; F8W7P8; Q5JSL6
Background:
Rho guanine nucleotide exchange factor 9, also known as Collybistin, plays a pivotal role in the nervous system by acting as a guanine nucleotide exchange factor (GEF) for CDC42. This protein is instrumental in promoting the formation of GPHN clusters, which are crucial for synaptic function and plasticity.
Therapeutic significance:
The protein's involvement in Developmental and epileptic encephalopathy 8, a disorder characterized by severe neurologic features including hyperekplexia, seizures, and intellectual disability, underscores its therapeutic significance. Understanding the role of Rho guanine nucleotide exchange factor 9 could open doors to potential therapeutic strategies for this debilitating condition.